Canaccord Genuity Reiterates Buy on KORU Medical Systems, Maintains $3 Price Target
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Caitlin Cronin has reiterated a Buy rating on KORU Medical Systems (NASDAQ:KRMD) and maintained a price target of $3.

December 07, 2023 | 3:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity analyst Caitlin Cronin maintains a Buy rating on KORU Medical Systems with a $3 price target.
The reiteration of a Buy rating by a Canaccord Genuity analyst, along with the maintenance of a $3 price target, is a positive endorsement for KORU Medical Systems. This could lead to increased investor confidence and a potential uplift in the stock price in the short term, as market participants may view the analyst's opinion as a credible signal of the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100